Boehringer provides update on iclepertin Phase III program in schizophrenia

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met.1–6 Overall, no statistically significant effects on cognition or functioning were observed in patients treated with iclepertin versus placebo at six months.1 All three trials demonstrated that iclepertin, a glycine transporter 1 (GlyT1) inhibitor, was generally well tolerated, with a safety profile that remains consistent with previous studies.1,2,7

“While these findings are disappointing, we remain dedicated to finding effective solutions for those living with serious mental illnesses. Our innovative pipeline includes over 20 additional investigative therapies in all stages of development and in different disease areas including schizophrenia and major depressive disorder,” said Shashank Deshpande, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “In the near future more can be expected. Our gratitude goes to the patients and clinical investigators whose time and commitment made this research possible.”  

CONNEX was the largest program for cognitive impairment in schizophrenia to date. Boehringer believes that the results will aid scientific understanding and inform future research for patients living with cognitive impairment in schizophrenia, an area of high unmet need with no approved targeted pharmaceutical treatment options available.8,9 Full efficacy and safety data will be submitted for presentation at an upcoming medical meeting. 

About cognitive impairment in schizophrenia 

Schizophrenia affects approximately 24 million people worldwide.10 Cognitive impairment is one of the three core symptom domains of schizophrenia, along with positive and negative symptoms.11 Cognitive impairment affects more than 80% of people with this condition, manifesting early in patients’ lives, and representing a leading cause of disability and impairment in daily functioning.8,9,12 People with schizophrenia often face cognitive challenges that impact their problem-solving abilities, attention and memory.8,9 These problems can make it difficult to live an independent and productive life.8,9 They can also cause a person to struggle with simple tasks such as attending appointments, which can make treatment difficult.8,9 

There are no approved targeted pharmaceutical treatments for cognitive impairment in schizophrenia.8,9

About iclepertin and the CONNEX clinical program 

Iclepertin (BI 425809), an investigational oral inhibitor of glycine transporter 1 (GlyT1), was studied as a potential treatment for cognitive impairment in adults with schizophrenia.1–6 Iclepertin has not been approved by any regulatory authorities.  

CONNEX was a Phase III clinical program designed to assess the safety and efficacy of iclepertin for improving cognitive impairment in adults with schizophrenia.2–6 The program comprised three clinical trials, all of which were randomized, double-blind, placebo-controlled parallel group trials investigating treatment with oral iclepertin 10 mg once daily over a 26-week period in adults with schizophrenia who received stable antipsychotic treatment.2–6 The CONNEX clinical program enrolled 1,840 patients in 41 countries.4–6  

Boehringer Ingelheim decided to discontinue the long-term extension trial, CONNEX-X, effective immediately.13

Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com. 

Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. 

References: 

Boehringer Ingelheim. Data on File. Rosenbrock H, Desch M, Wunderlich G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1557–1566. doi:10.1007/s00406-023-01576-z. Falkai P, Reuteman-Fowler C, Blahova Z, Ikezawa S, Marder SR, Krystal JH. Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme. Eur Psychiatry. 2023;66(Suppl 1):S637. doi:10.1192/j.eurpsy.2023.1325. ClinicalTrials.gov. NCT04846868. Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1). Available from: https://clinicaltrials.gov/study/NCT04846868. Accessed January 2025. ClinicalTrials.gov. NCT04846881. Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2). Available from: https://clinicaltrials.gov/study/NCT04846881. Accessed January 2025. ClinicalTrials.gov. NCT04860830. CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia. Available from: https://clinicaltrials.gov/study/NCT04860830. Accessed January 2025. Fleischhacker WW, Podhorna J, Gröschl M, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021;8(3):191–201. doi:10.1016/S2215-0366(20)30513-7. Kitchen H, Rofail D, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther. 2012;29(2):148–162. doi:10.1007/s12325-012-0001-4. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2(4):531–536. doi:10.2147/nedt.2006.2.4.531. World Health Organization. Schizophrenia. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Accessed January 2025. Stahl SM. Stahl’s Essential Psychopharmacology. 4th ed. Cambridge University Press; 2013. Mosiołek A, Gierus J, Koweszko T, Szulc A. Cognitive impairment in schizophrenia across age groups: a case-control study. BMC Psychiatry. 2016;16:37. doi:10.1186/s12888-016-0749-1. ClinicalTrials.gov. NCT05211947. A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study. Available from: https://clinicaltrials.gov/study/NCT05211947. Accessed January 2025.


Attachment

  • Boehringer healthcare HCP

Boehringer provides update on iclepertin Phase III program in schizophrenia


THỦ THUẬT HAY

[Mac] Dùng Vox để nghe Youtube

Vox là phần mềm miễn phí trên App Store. Mình vẫn dùng nó để nghe FLAC và các chuẩn âm thanh mà iTune không hỗ trợ. Mình cũng thường xuyên nghe nhạc trên Youtube. Hồi xưa chưa biết...

Hướng dẫn gỡ bỏ triệt để phần mềm, ứng dụng trên Windows

Tuy nhiên, cùng với thời gian sử dụng, chiếc máy tính ấy sẽ được hàng trăm phần mềm, ứng dụng và tiện ích khác nhau, khiến máy tính trở nên quá tải.

Pin iPhone 6s dùng được bao lâu?

Nếu bạn đang băn khoăn về thời lượng pin của chiếc iPhone 6s liệu có đáp ứng nhu cầu sử dụng của bạn hay không. Hôm nay, chúng tôi sẽ phần nào giải đáp.

World Cup 2018 sắp tới rồi, đổi ảnh nền đội bạn thích thôi

Những hình ảnh này cực 'chất' này đều được đăng tải bởi kênh truyền hình thể thao nổi tiếng thế giới ESPN và mình đã crop lại để phù hợp trong phạm vi bài viết.

Hướng dẫn cách cài đặt độ phân giải màn hình trên KOPlayer

Từ những tính năng sử dụng cho đến cài đặt giả lập, một trong số những tính năng giúp tối ưu hóa giả lập này đó là cài đặt độ phân giải phù hợp với kích cỡ màn hình. Nếu màn hình của bạn có độ phân giải lớn thì bạn có

ĐÁNH GIÁ NHANH

Đánh giá QNAP TAS-268 – Hỗ trợ đa phương tiện, mở rộng đến 20TB

QNAP TAS-268 không chỉ hướng đến môi trường SOHO (small office home office) cần kiểm soát, tập trung hóa dữ liệu mà còn phù hợp cả với nhu cầu sử dụng khác nhau trong gia đình....

Đánh giá loa vi tính 2.0 GoldSound GS51- Bluetooth

Nhân vật chính ngày hôm nay nay của chúng ta là mẫu loa GoldSound GS51-Bluetooth, là bản cải tiến thứ 3 của dòng loa vi tính 2.0 của công ty GoldSound.

Đánh giá Xiaomi Mi Mix, phablet đáng mua nhất hiện tại

Mặc dù không phải là hãng smartphone tiên phong về thiết kế không viền, nhưng những gì mà Xiaomi làm được với Mi Mix quả thật là một cú 'đấm' mạnh mẽ nhất vào những tên tuổi khổng lồ trong ngành công nghiệp smartphone